The Biacore 4000 from GE Healthcare provides high‑throughput, label‑free molecular interaction analysis for antibody and small‑molecule drug development.
The Biacore 4000 is a label‑free interaction analysis system designed for large‑scale screening and characterization in drug discovery. It features four independent flow cells, each with five detection points, enabling parallel injection of up to 16 targets per run.
The system delivers up to 4,800 interactions in 24 hours, supports automated sample handling, advanced LIMS integration, and complies with 21 CFR Part 11. Optional software packages extend functionality for antibody and small‑molecule workflows, while the hardware can operate unattended for up to 60 hours. This manual is written in Chinese.
| Number of flow cells | 4 |
|---|---|
| Detection points per flow cell | 5 |
| Maximum interactions per 24 h | 4800 |
| Parallel injection capacity | 16 targets per run |
| Unattended operation time | 60 hours |
| Regulatory compliance | 21 CFR Part 11 |
It can analyze up to 4,800 interactions within a 24‑hour period.
Each of the four flow cells contains five detection points.
The system can inject up to 16 targets simultaneously per run.
Yes, the software complies with 21 CFR Part 11.